Cell No. : Cell Name RCB1297 : HYT-1  update : 2024/01/17
Comment			A human cell line derived from acute myeloid leukemia (AML). Secondary AML. Able to differentiate to megakaryocyte-like cells.
Comment from the depositor
Terms and conditions			There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form			Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Depositor	Hamaguchi, Hiroyuki
		Originator	Hamaguchi, Hiroyuki
		Year of deposit	1997
		Animal	_human < Mammals
		Genus	Homo
		Species	sapiens
		Gender	Male
		Age at sampling	62 years
		Tissue	bone marrow
		Disease name	AML
		Classification	cancer
		Year of origin	1993
		Lifespan	infinite
		Morphology	other
		Cellosaurus(Expasy)	CVCL_4639
			deposit info	lot info
		Medium	Medium List
		Culture type		Suspension cells
		Culture method		浮遊細胞の培養に関する一般的な注意(Japanese)
		Culture medium		RPMI1640 + 10% FBS (heat inactivated) + 10ng/ml human G-CSF
		Antibiotics		Free
		Passage method		dilution
	Culture information	Passage ratio		1 : 4 split
		SC frequency		Subculture : once/week, Medium Renewal : 2 times/week
		Temperature		37 ℃
		CO2 concentration		5 %
		Freeze medium		Medium + 10% DMSO
		Freezing method		Slow freezing
		Mycoplasma/Acholeplasma		(-)
		Virus (HIV)		LT 400
		Virus (HTLV-1)		(-)
		Isozyme		LD, NP, G6PD
		Chromosome mode		44-47(50) : 44(5),45(40),46(4),47(1)
		STR(human)		OK
Images			deposit info	lot info
Reference information		Reference	0
		User's Publication	2

Top

Reference

Top

User's Publication

21650  Matsuo H, Inagami A, Ito Y, Ito N, Iyoda S, Harata Y, Higashitani M, Shoji K, Tanaka M, Noura M, Mikami T, Kato I, Takita J, Nakahata T, Adachi S.  Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes.  Commun Biol  2024  7(1):123  PubMed ID: 38267545   DOI: 10.1038/s42003-024-05811-8

21555  Katsuyama N, Kawase T, Barakat C, Mizuno S, Tomita A, Ozeki K, Nishio N, Sato Y, Kajiya R, Shiraishi K, Takahashi Y, Ichinohe T, Nishikawa H, Akatsuka Y.  T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.  Nagoya J Med Sci  2023  85(4):779-796  PubMed ID: 38155626   DOI: 10.18999/nagjms.85.4.779